

Medical Policies			
Policy Title	Summary	Products Affected	Effective Date
Adstiladrin	Ad hoc review. <ul style="list-style-type: none"> <li>Updated Medicare Variation.</li> </ul>	Medicare Advantage	1/1/2026
Continuous Glucose Monitors	Annual review. <ul style="list-style-type: none"> <li>Changed order of paragraphs in eligibility criteria, but no changes made to criteria themselves.</li> </ul>	All products	1/1/2026
Homeless Medical Respite Services	New policy; formerly part of the Long-Term Services and Supports policy.	One Care and SCO	1/1/2026
Insulin Pumps	Annual review. <ul style="list-style-type: none"> <li>No changes.</li> </ul>	All Products	1/1/2026
Long-Term Services and Supports	Ad hoc review of policy. <ul style="list-style-type: none"> <li>Separated Homeless Medical Respite Services criteria into its own policy.</li> <li>Added criteria from former Respite Services policy into this policy.</li> </ul>	One Care and SCO	1/1/2026
Omisirge	Ad hoc review. <ul style="list-style-type: none"> <li>Updated Medicare variation.</li> </ul>	Medicare Advantage	1/1/2026
Personal Care Attendant and Personal Care Management Agency Services	Ad hoc review of policy. <ul style="list-style-type: none"> <li>Added criteria for Personal Care Management Agency services.</li> <li>Added criteria for Complex Care services.</li> </ul>	One Care and SCO	1/1/2026
Respite Services	Retired separate policy; added the criteria to the Long-Term Services and Supports policy.	One Care and SCO	1/1/2026
Vitamin D Testing and Screening in Adults	Annual review. <ul style="list-style-type: none"> <li>No changes.</li> </ul>	All products	1/1/2026
Prime Therapeutics: Abecma	Ad hoc review. <ul style="list-style-type: none"> <li>Clarified difference between auth durations for initial and renewal periods.</li> <li>REM criterion removed.</li> <li>Added NCCN guidance for additional uses of regimen.</li> </ul>	Commercial	2/1/2026
Prime Therapeutics: Aucatzyl	Ad hoc review.	Commercial	2/1/2026

	<ul style="list-style-type: none"> <li>Clarified difference between auth durations for initial and renewal periods.</li> <li>Updated FDA indications and NCCN guidance.</li> <li>Updated code list.</li> </ul>		
Prime Therapeutics: Breyanzi	Ad hoc review. <ul style="list-style-type: none"> <li>Clarified difference between auth durations for initial and renewal periods.</li> <li>REM criterion removed.</li> <li>Expanded access per NCCN guidance.</li> </ul>	Commercial	2/1/2026
Prime Therapeutics: Carvykti	Ad hoc review. <ul style="list-style-type: none"> <li>Clarified difference between auth durations for initial and renewal periods.</li> <li>REM criterion removed.</li> <li>Added NCCN guidance for additional uses of regimen.</li> </ul>	Commercial	2/1/2026
Prime Therapeutics: Kymriah	Ad hoc review. <ul style="list-style-type: none"> <li>Clarified difference between auth durations for initial and renewal periods.</li> <li>REM criterion removed.</li> <li>Expanded access per NCCN guidance.</li> </ul>	Commercial	2/1/2026
Prime Therapeutics: Ryoncil	New policy.	Commercial	2/1/2026
Prime Therapeutics: Tecartus	Ad hoc review. <ul style="list-style-type: none"> <li>Clarified difference between auth durations for initial and renewal periods.</li> <li>REM criterion removed.</li> <li>Updated info on patient monitoring.</li> </ul>	Commercial	2/1/2026
Prime Therapeutics: Yescarta	Ad hoc review. <ul style="list-style-type: none"> <li>Clarified difference between auth durations for initial and renewal periods.</li> <li>REM criterion removed.</li> <li>Updated criteria based on NCCN guidelines.</li> </ul>	Commercial	2/1/2024